by Redaktion LCGC | Apr 30, 2015
ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability. Scheffler M, Schultheis A, Teixido C, Michels S, Morales-Espinosa D, Viteri S, Hartmann W, Merkelbach-Bruse S, Fischer R, Schildhaus HU, Fassunke J, Sebastian...
by Redaktion LCGC | Mar 20, 2015
Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort. Mazières J, Zalcman G, Crinò L, Biondani P, Barlesi F, Filleron T, Dingemans AM, Léna H, Monnet I, Rothschild SI, Cappuzzo F, Besse B, Thiberville L, Rouvière...
by Redaktion LCGC | Mar 16, 2015
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Rizvi NA, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ,...
by Redaktion LCGC | Feb 1, 2015
Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: An expert consensus. Cappuzzo F, Moro-Sibilot D, Gautschi O, Boleti E, Felip E, Groen HJ, Germonpré P, Meldgaard P, Arriola E, Steele N, Fox J, Schnell P, Engelsberg A, Wolf J. Journal:...
by Redaktion LCGC | Jan 10, 2015
Modeling tumor dynamics and overall survival in advanced non-small-cell lung cancer treated with erlotinib. Suleiman AA, Frechen S, Scheffler M, Zander T, Kahraman D, Kobe C, Wolf J, Nogova L, Fuhr U. Journal: J Thorac Oncol Veröffentlichung: 10. Jan. 2015 (Epub 10....
